Details

Autor(en) / Beteiligte

• Antonini, T. M.
• Sebagh, M.
• Roque‐Afonso, A. M.
• Teicher, E.
• Roche, B.
• Sobesky, R.
• Coilly, A.
• Vaghefi, P.
• Adam, R.
• Vittecoq, D.
• Castaing, D.
• Samuel, D.
• Duclos‐Vallée, J.‐C.

Titel

Fibrosing Cholestatic Hepatitis in HIV/HCV Co‐Infected Transplant Patients—Usefulness of Early Markers After Liver Transplantation

Ist Teil von

• American journal of transplantation, 2011-08, Vol.11 (8), p.1686-1695

Ort / Verlag

Malden, USA: Blackwell Publishing Inc

Erscheinungsjahr

2011

Link zum Volltext

Quelle

Wiley Online Library

Beschreibungen/Notizen

• We characterized fibrosing cholestatic hepatitis (FCH) in a large cohort of HIV/HCV co‐infected patients. Between 1999 and 2008, 59 HIV infected patients were transplanted for end‐stage liver disease due to HCV. Eleven patients (19%) developed FCH within a mean period of 7 months [2–27] after liver transplantation (LT). At Week 1 post‐LT, the mean HCV viral load was higher in the FCH group: 6.13 log10 IU/mL ± 1.30 versus 4.9 log10 IU/mL ± 1.78 in the non‐FCH group, p = 0.05. At the onset of acute hepatitis after LT, activity was moderate to severe in 8/11 HIV+/HCV+ patients with FCH (73%) versus 13/28 (46%) HIV+/HCV+ non‐FCH (p = 0.007) patients. A complete virological response to anti‐HCV therapy was observed in 2/11 (18%) patients. Survival differed significantly between the two groups (at 3 years, 67% in non‐FCH patients versus 15% in FCH patients, p = 0.004). An early diagnosis of FCH may be suggested by the presence of marked disease activity when acute hepatitis is diagnosed and when a high viral load is present. The initiation of anti‐HCV therapy should be considered at this point. An early diagnosis of fibrosing cholestatic hepatitis, which develops after liver transplantation in 19% of a cohort of HIV/HCV coinfected patients, is feasible.